Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment in 2025
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Dr. McFarland to Talk Tomorrow
View:
Post by Eoganacht on Apr 14, 2022 12:02pm

Dr. McFarland to Talk Tomorrow

If you happen to be in the Washington DC area tomorrow, Dr McFarland will be giving an hour long talk at the University of Maryland which is open to the public. I'm not sure if it's possible to attend virtually. I emailed Dr. Huang about it. I will post login information if he gets back to me.

BIOE Seminar: Tackling Cancer and Infection with Light-Responsive Molecules

University of Maryland
 
A. James Clark Scool of Engineering
Fischell Department of Engineering
 
Friday, April 15, 2022
9:00 a.m.-10:00 a.m.
A. James Clark Hall, Room 2121
 
Joe Huang
hchuang@umd.edu
 
About the speaker: 
 
Sherri McFarland's research interests include translational drug discovery for cancer and infection, coordination complexes, metallodrugs and medicinal inorganic chemistry, photodrugs and photomedicine, photodynamic therapy (PDT), photochemotherapy (PCT), photoactivated chemotherapy (PACT), phototherapy, photochemistry and photophysics, chemical synthesis, chemical biology, immunomodulators and immunomodulating therapies, photosensitizing natural products, photodynamic inactivation (PDI). 
 
Abstract: 
 
Photomedicine is an interdisciplinary field where chemistry and light meet to fight disease. Photodynamic therapy (PDT) is a special branch of photomedicine that employs a sensitizer molecule, light, and oxygen to destroy target cells with spatiotemporal selectivity. Using a multidisciplinary approach, we have introduced both synthetic compounds and natural products as photosensitizers for PDT. Both have successfully completed Phase 1 clinical trials and are currently in Phase 2 clinical trials. This seminar will share some of our stories in developing metallodrug photosensitizers for treating bladder cancer and photoactive plant extracts for improving oral health. If time permits, some new directions will be highlighted.
 
Audience: Public 
Comment by Eoganacht on Apr 14, 2022 1:55pm
I heard back from the University of Maryland. The best way to attend this event is to sign up for the weekly BIOE Weekly Events email at this link:  https://bioeumd.wufoo.com/forms/m815q710guwqno/ They will send a reminder email tomorrow morning with the Zoom link.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed in 2025, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250